John G. Kuhn, PharmD

home / authors / john-g-kuhn-pharmd

Articles

Influence of Anticonvulsants on the Metabolism and Elimination of Irinotecan

August 1st 2002

The hepatic metabolism and biliary secretion of irinotecan (CPT-11, Camptosar) and metabolites is complex and involves cytochrome P450 isoenzymes, carboxylesterases, glucuronosyltransferase, and the ATP-dependent export pumps MRP-2 and MXR. Enzyme-inducing antiepileptic drugs (EIAEDs) such as phenytoin and carbamazepine are known to induce several of the metabolic pathways relevant to ininotecan’s elimination. The North American Brain Tumor Consortium phase I study is designed to determine the maximum tolerated dose and pharmacokinetics of irinotecan given every 3 weeks to patients who are receiving EIAEDs.

Alternative Dosing Schedules for Irinotecan

Mace L. Rothenberg, MD;John G. Kuhn, PharmD;Larry J. Schaaf, PhD;Ronald L. Drengler, MD;S. Gail Eckhardt, MD;Miguel A. Villalona-calero, MD;Eric K. Rowinsky, MD;Daniel D. Von Hoff, MD;Langdon L. Miller, MD;Rrobert G. Petit, PhD;Lisa Hammond, MD

August 1st 1998

Most of the clinical experience with irinotecan (CPT-11 [Camptosar]) has been with either a weekly or an every-3-week schedule. Recent phase I trials have explored new routes and schedules of administration. One approach